Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated
